EXPERIENCE WITH THE DRUG MEMANTINE IN PATIENTS WITH FOCAL EPILEPSY AND COGNITIVE IMPAIRMENT

Abstract: cognitive impairment of varying degrees of severity identified in patients with focal epilepsy in 40-50% of cases. The incidence and severity of cognitive impairment depends on the cause epileptic seizures, localization of the lesion, antiepileptic therapy, and other factors. It should be noted that the correction capability of cognitive disorders in patients with epilepsy are somewhat limited because number of drugs used for the treatment are in the instructions for use as contraindications and indications of use ostoozhnostyu in patients with epilepsy. This work reflects the results of a prospective uncontrolled focal observations efficiency NMDA-receptor antagonist: This drug memantine (Noodzheron). The study involved 50 patients with focal epilepsy and having symptoms of cognitive deficits of varying severity. Evaluating the effectiveness carried out in 2 months from the start of the reception, the dosage of 5.10 mg × 1 time per day. After the treatment, a statistically significant improvement in cognitive function based on the results of tests: Mini-mental state examination, clock drawing test, the test Luria test “symbols and numbers.” Noodzheron taking the drug had no effect on the frequency of epileptic seizures

LEVETINOL IN COMPLEX TREATMENT OF FOCAL EPILEPSY (EXPERIENCE OF EPILEPTOLOGIST IN OUTPATIENT NETWORK, MOSCOW)

Abstract: prescription of Levetinol in regimen of integrated adjunctive therapy in 30 patients with symptomatic and cryptogenic focal forms of epilepsy with poorly controlled seizures, receiving the reference probe of antiepileptic drugs, was accompanied by the attainment of a higher therapeutic effect. Remission with an average effective dose of the drug 1437.5 mg/day was observed in 6, reduction of attacks by 75% – in 8 patients. Levetinol significantly affect the indicators of anxiety and depression in the reduction of symptoms of affective disorders

EXPERIENCE OF PROLONGED VALPROATE USE IN ADULT PATIENTS WITH FOCAL FORMS OF EPILEPSY (RESULTS OF OBSERVATION HELD IN OUT-PATIENT CLINICS OF MOSCOW)

Results of Depakine Chronosphere use in Moscow city out-patient clinics are demonstrated in the article. 48 patients with focal forms of epilepsy (cryptogenic and symptomatic) were examined: 32 men and 16 women in age of 16 - 59 years with different duration of disease and different types of seizures. Depakine Chronosphere was indicated to patients who were already taking antiepileptic drugs in monotherapy with efficacy of 50% and more, and also to patients with drug remission, but with side effects, requiring changes of current indications. Results of the observation demonstrated high efficacy of Depakine Chronosphere in adult patients with different forms of focal epilepsy in monotherapy and also its use possibility in case of noneffective or poor tolerability of other valproates and carbamazepine

EXPERIENCE GENERIC VALPROATE IN ADULTS WITH FOCAL EPILEPSY (RESULTS THE OBSERVATIONS IN MOSCOW HEALTH FACILITY OUTPATIENT NETWORK)

Abstract: In this article the results of the study of focal observations of interchangeability of generic Konvuleksa to retard and original probe Depakine chrono on Valparin XR (production Torrent Pharmaceuticals, India) in patients with various forms of epilepsy. In focal observations was attended by 30 patients with focal forms of epilepsy: 17 men and 13 women aged 23 to 62 years with different disease duration and the presence of seizures, which differ according to the type and etiology. Based on these results it can be concluded that the transfer of patients with previous therapy Valparin XR generally accompanied by a stable level of seizure control

EXPERIENCE OF USING LAKOSAMID IN VARIOUS FORMS OF EPILEPSY (The results of observational study in city outpatient health care chain of Moscow)

This paper presents experience of using Vimpat in outpatient health care chain of Moscow. In the observational study were attended 49 patients with difficult for treatment focal forms of epilepsy (cryptogenic and symptomatic forms). Vimpat used in complex therapy in the mean effective dose of 300-400 mg per day. As a result, the data on a cohort of Russian patients showed that Vimpat demonstrate a sufficiently high clinical efficacy (55%, p<0.01) and appropriate for use in patients with difficult for treatment forms of epilepsy in complex therapy when the previous treatment was ineffective

EXPERIENCE OF TREATMENT WITH GENERIC LAMOTRIDJIN IN DIFFERENT FORMS OF EPILEPSY (The results of focus observation in out-patient clinics network of Moscow city public healthcare services)

Focused observational study on efficacy, tolerability and quality of life in adult patients with different forms of epilepsy taking combined therapy with lamotrigine (Sazar). 32 patients (19 men and 13 women), 23-79 years old with focal forms (cryptogenic and symptomatic) epilepsy with different disease duration and presence of of different type and etiology seizures were enrolled into the study. Patients having been taken various antiepileptic drugs in monotherapy with different efficacy degree were observed. Patients sample included 20 patients, receiving valproic acid in various dosages and 12 patients, receiving topiramate. Sazar was added as a second drug with initial dosage of 25 mg daily. Results of focused observation allow us to make conclusion of possible expedience of Sazar indication, especially in patients in whom therapy with valproic acid is less effective

EXPERIENCE OF TREATMENT OF DIFFERENT FORMS OF EPILEPSY WITH GENERIC TOPIRAMATE (The results of focus observation in out-patientclinics network of Moscow city public healthcare services)

Current work is dedicated to analysis of treatment with generic topiramate in mono- as well as in polytherapy in patients with different forms of epilepsy. Forclinical assessmentsHospital Anxiety and Depression Scale (HADS), quality of life questionnaire for patients with epilepsy (QOLIE-10) and efficacy primary assessment based on decrease in frequency of seizures and adverse events before and after switching to generic topiramate were used. As a result of focus investigation switch to Topsaver was associated with maintenance of stable therapeutic effect in more, than 80% of cases. No negative dynamics in changes of HADS and QOLIE-10 points were observed